Aug. 4 at 2:09 PM
$GLUE — updating my thinking after going through everything the company has published.
The July 31 drop was entirely a reaction to someone else’s failure. Novo Nordisk’s anti-inflammatory heart drug didn’t work, and GLUE fell almost 40%in sympathy. No GLUE data came out.
Analysts barely moved their targets — Jefferies 31→30, Guggenheim 34→30, both still positive — while the stock fell 27%.
That said, Novo’s failure does real damage to how management has been pitching this. They’d been selling it on a blood marker. That marker just got discredited.
2— what the drug actually does, in plain terms:
Think of inflammation like a fire alarm chain. Novo’s drug shut off the alarm near the end of the chain. Didn’t help.
GLUE’s pill works at the very start. It stops immune cells from bursting open in the first place.
Why that might matter: when those cells burst, they die and spill debris into the artery wall. That debris is what builds the soft gunk inside a plaque that eventually ruptures and causes a heart attack. Live cells clean the mess up. Dead ones become the mess.
So it’s less “reduce inflammation” and more “stop killing the cleanup crew.”
3— two things buried in the annual report that aren’t in any slide deck:
1. In a heart-inflammation animal study, GLUE’s pill beat an injectable antibody drug of the type already approved for that condition.
2. Ozempic partly does the same thing GLUE’s drug does — it turns down the same protein, by about half. And when they combined the two in monkeys, weight loss went from 17% to over 23%, with the fat coming off the belly and muscle preserved.
That second one is a weight-loss angle sitting in a document almost nobody reads.
4— the parts of this company that have nothing to do with the failed heart trial:
• A second drug fully licensed to Novartis — Novartis pays for the trials, GLUE keeps 30% of US profits, up to
$2.1B in payments
• A second Novartis deal signed last September:
$120M paid up front, up to
$5.4B possible
• A Roche partnership on top of that
• A cancer program with unusually clean targeting data, filing to start trials this year
• A prostate cancer drug that hit in 5 of 5 patients with a specific mutation
• Their discovery method was published in Science
Roughly
$610M in the bank, funded into 2029, no debt.
5— the honest bear case, and what I’m watching:
The worry: their next big heart trial enrolls almost exactly the same kind of patients where Novo just failed. And the “protect the cleanup crew” idea has never actually been measured inside a real artery — not once, in any study. It’s a good theory with a hole in the middle.
Watching Thursday: whether Novartis has started its trials, and whether they’ve changed the heart trial design.
But the real tell is the gout study starting around year-end. Short, cheap, clear yes-or-no answer, and a similar drug already works there.
Long. Not advice, do your own work.
